Promising advancements emerged in neonatal and pediatric healthcare. Airway Therapeutics announced an expanded multinational Phase III trial for zelpultide alfa, targeting bronchopulmonary dysplasia in preterm neonates. Concurrently, research exploring intratracheal administration of budesonide combined with surfactant aims to reduce lung injury in extremely premature infants. Additionally, studies highlighted how loneliness exacerbates depression in adolescent and young adult cancer survivors, underscoring the importance of integrating mental health in pediatric care.